文献速递血栓与止血

儿童诱发性静脉血栓形成伴抗磷脂抗体患者的结局:Kids-DOTT 试验结果

Outcomes in children with provoked venous thrombosis and antiphospholipid antibodies: findings from the Kids-DOTT trial.
PubMed 文献 · Blood Adv · 2024-01-01

多中心 Kids-DOTT 试验比较了 524 例小于 21 岁首次急性诱发性静脉血栓栓塞(VTE)患儿中抗磷脂抗体(aPL)阳性者的结局。入组时 116 例(22%)aPL 阳性,随访中 11 例(10%)为持续性 aPL 并符合抗磷脂抗体综合征(APS)标准。与短暂性或低滴度 aPL 组相比,APS 组年龄更大(15.8 岁 vs 9.9 岁,P=.014),症状性复发性 VTE 风险更高(18% vs 1%;OR 12.2,95%CI 1.4-108,P=.025)。

要点

  • 急性诱发性 VTE 患儿中 aPL 常见(22%),多为短暂性且无临床意义。
  • 符合 APS 标准的患儿症状性复发性 VTE 风险为 18%,短暂性或低滴度 aPL 组为 1%。
  • APS 组抗凝相关临床相关出血风险为 9%,短暂性或低滴度 aPL 组为 0%,差异未达统计学显著。

核心结论

  • 急性诱发性 VTE 的年轻患者中 aPL 常见,且多为短暂性和无临床意义。
  • 符合 APS 标准的诱发性 VTE 患者较短暂性或低滴度 aPL 患者似乎有更高的复发性 VTE 风险。
  • 未来协作研究应探讨符合 APS 标准的诱发性 VTE 儿童的最佳 VTE 管理。

研究设计与样本

  • 多中心儿童血栓形成治疗时长评估(Kids-DOTT)试验,纳入年龄小于 21 岁、首次急性诱发性 VTE 且诊断时 aPL 阳性的患者。
  • aPL 于入组时检测,阳性者在 VTE 诊断后 6 周复测,后续检测由治疗血液科医生酌情决定。
  • 共 524 例患者,116 例(22%)入组时 aPL 阳性。
  • 试验注册号为 NCT00687882。

主要发现

  • 随访时 70 例(60%)为短暂性(n=66)或低滴度 aPL(n=4),11 例(10%)为持续性 aPL 并符合 APS 标准,35 例(30%)未复测。
  • APS 组年龄大于短暂性或低滴度 aPL 组(15.8 岁 vs 9.9 岁;P=.014)。
  • APS 组症状性复发性 VTE 风险为 18%,短暂性或低滴度 aPL 组为 1%(OR 12.2;95%CI 1.4-108;P=.025)。
  • APS 组抗凝相关临床相关出血风险为 9%,短暂性或低滴度 aPL 组为 0%(OR 20.1;95%CI 0.7-558;P=.077),差异未达统计学显著。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Few studies have prospectively evaluated the incidence and outcomes in children with provoked venous thromboembolism (VTE) and transient or persistent antiphospholipid antibodies (aPLs). We compared outcomes of patients aged <21 years with a first-episode acute provoked VTE and positive aPL at diagnosis, enrolled in the Multicenter Evaluation of the Duration of Therapy for Thrombosis in Children trial. aPLs were tested at enrollment and, when positive, repeated at 6 weeks after VTE diagnosis. Subsequent testing was performed at the discretion of the treating hematologist. Of 524 patients, 116 (22%) had positive aPLs at enrollment. At follow-up, 70 (60%) had transient (n = 66) or low-titer aPLs (n = 4), 11 (10%) had persistent aPLs meeting the criteria for antiphospholipid antibody syndrome (APS), and 35 (30%) had no repeat testing. Patients with APS were older (15.8 vs 9.9 years; P = .014) and had a statistically significant higher risk of symptomatic recurrent VTE (18% vs 1%; odds ratio [OR], 12.2; 95% confidence interval [CI], 1.4-108; P = .025) and a statistically nonsignificant but clinically meaningful difference in the risk of anticoagulant-related clinically relevant bleeding (9% vs 0%; OR, 20.1; 95% CI, 0.7-558; P = .077) compared with those in the transient or low-titer aPL group. In conclusion, aPLs are common in young patients with acute provoked VTE and are mostly transitory and clinically insignificant. Patients with APS and provoked VTE appear to have an increased risk of recurrent VTE compared with patients with transitory or low-titer aPLs. Future collaborative studies should investigate the optimal VTE management for children with provoked VTE who meet the criteria for APS. The trial was registered at www.ClinicalTrials.gov as #NCT00687882.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Betensky M, Mosha M, Tarango C, et al. Outcomes in children with provoked venous thrombosis and antiphospholipid antibodies: findings from the Kids-DOTT trial. Blood Adv. 2024. PMID: 39321425. doi:10.1182/bloodadvances.2024014415

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。